NCNA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

-2.600

-99.41%

Estimates Revision

The market is revising No Change the revenue expectations for NuCana plc (NCNA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -39.09%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-39.09%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for NuCana PLC (NCNA.O) is -70.00, compared to its 5-year average forward P/E of -11.39. For a more detailed relative valuation and DCF analysis to assess NuCana PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.39

Current PE

-70.00

Overvalued PE

19.19

Undervalued PE

-41.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.23

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.55

Undervalued EV/EBITDA

-1.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.26

Current PS

0.00

Overvalued PS

12.33

Undervalued PS

-7.80

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NCNA News & Events

Events Timeline

No data

News

9.5

2025-09-12Benzinga

Major Stocks Including IBEX, Tesla, IonQ, and Warner Bros. Discovery Rise on Friday

7.0

2025-09-05SeekingAlpha

NuCana Gets Compliance Notice from Nasdaq

9.0

2025-09-03Newsfilter

NuCana to Showcase Findings on NUC-7738's Combined Effect with PD-1 Inhibitors at ESMO Congress 2025

People Also Watch

Frequently Asked Questions

What is NuCana PLC (NCNA) stock price today?

The current price of NCNA is 3.6 USD — it has decreased -0.55 % in the last trading day.

What is NuCana PLC (NCNA)'s business?

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.

What is the price predicton of NCNA Stock?

Wall Street analysts forecast NCNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NCNA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is NuCana PLC (NCNA)'s revenue for the last quarter?

NuCana PLC revenue for the last quarter amounts to -3.57M USD, decreased -29.90 % YoY.

What is NuCana PLC (NCNA)'s earnings per share (EPS) for the last quarter?

NuCana PLC. EPS for the last quarter amounts to 1342000.00 USD, decreased -129.27 % YoY.

What changes have occurred in the market's expectations for NuCana PLC (NCNA)'s fundamentals?

How many employees does NuCana PLC (NCNA). have?

NuCana PLC (NCNA) has 20 emplpoyees as of January 09 2026.

What is NuCana PLC (NCNA) market cap?

Today NCNA has the market capitalization of 14.98M USD.